Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion

The deal targets KRAS-driven tumors, which J&J says have limited treatment options and survival measured in months

添加评论
点赞收藏
点踩分享查看原文
评论
?
参与讨论